ntane) as a neutral ligand. A new coordination mode of ascorbic acid (O2 and O3 protected) as an O5,O6-diolate chelating ligand has been characterised in solution by NMR spectroscopy and in the solid state by X-ray crystallography. The firstexample of a platinum complex that contains dehydroascorbic acid, 7, has also been prepared and its X-ray crystalstructure has been determined. The antiproliferative
L-抗坏血酸作为阴离子双齿配体的多种配位模式已被用于制备铂 (II) 配合物 1-7,其中包含磷烷或 R,R-dach (1R,2R-二氨基环己烷) 作为中性配体,其中 O2 、O3、O5、O6 和 C2 作为阴离子供体官能团。提出了已知 O2,O3 配合物的替代合成路线,并且通过引入 PTA(1,3,5-三氮杂-7-磷金刚烷)作为中性配体,提高了它们在水中的溶解度。抗坏血酸(O2 和 O3 保护)作为 O5,O6-二醇螯合配体的新配位模式已通过 NMR 光谱在溶液中和在固态中通过 X 射线晶体学表征。含脱氢抗坏血酸 7 的铂络合物的第一个例子也已制备,并已确定其 X 射线晶体结构。
[EN] METHODS FOR PREPARING CELL TARGETING CONJUGATES AND CONJUGATES OBTAINABLE BY SAID METHODS<br/>[FR] PROCÉDÉS DE PRÉPARATION DE CONJUGUÉS DE CIBLAGE CELLULAIRE ET CONJUGUÉS OBTENUS PAR LESDITS PROCÉDÉS
申请人:LINXIS B V
公开号:WO2019125153A1
公开(公告)日:2019-06-27
The present invention relates to methods for preparing a cell targeting conjugate, which conjugate comprises a cell binding moiety conjugated to a secondary functional moiety. The present invention further relates to the cell targeting conjugates obtainable by said method, to a pharmaceutical composition comprising said conjugates and to the secondary functional moieties as such. The present invention also relates to the use of the cell targeting conjugates in the treatment of cancer.
Synthesis and antitumor activity of new trans-1R,2R-diaminocyclohexaneplatinum(II) complexes containing disubstituted sulfide groups
作者:S. Shamsuddin、Salaam Al-Baker、Zahid H. Siddik、Abdul R. Khokhar
DOI:10.1016/0020-1693(95)04735-2
日期:1996.1
Abstract A series of cationic platinum(II) complexes of the form [Pt(DACH)(R′R″S)Cl]NO 3 , (where DACH = trans -1 R ,2 R -diaminocyclohexane, and R′R″S = dimethylsulfide, diethysulfide, dipropylsulfide, diisopropylsulfide, diphenylsulfide, dibenzylsulfide, thioanisole and methyl- p -tolylsulfide) have been synthesized and characterized by elemental analysis, IR, 1 H and 195 Pt NMR spectroscopic techniques
PHOSPHATE OF PLATINUM COMPOUND AND PREPARATION METHOD THEREFOR
申请人:Beijing Showby Pharmaceutical Co., LTD.
公开号:US20210253619A1
公开(公告)日:2021-08-19
Provided is 2-(4-diethylamino)butylmalonic acid-(1R,2R)-(−)-1,2-cyclohexanediamine platinum(II) phosphate having high solubility, low hygroscopicity, and high stability and being suitable for preparing into various antitumor drug preparations. Also provided is a preparation method for amorphous 2-(4-diethylamino)butylmalonic acid-(1R,2R)-(−)-1,2-cyclohexanediamine platinum(II) phosphate. The method is simple to operate and is suitable for industrial implementation.
Process for the Preparation of an Anti-Tumor Platinum (II) - Complex
申请人:Maikap Golak Chandra
公开号:US20080207935A1
公开(公告)日:2008-08-28
We disclose here processes for making Platinum complex of general formula (I) where in, the conformation of 1,2-diaminocyclohexane is cis, trans-l or trans-d isomer and R
1
and R
2
combinedly make dicarboxylic acid having formulae (II), (III) and (IV), here in, the two carboxylic acid groups are on the same or on vicinal carbon atoms, n is zero or an integer ranging from 1 to 5 and R
3
is either hydrogen or a substituent with electron withdrawing or electron releasing effects exemplified by alkoxy, halo, and nitro groups by reacting a compound of formula M
2
PtX
4
wherein X represents halogen atom such as Cl or Br or thiocyanate with (i) 1,2-diaminocyclohexane (ii) source of silver ion selected from a silver compound containing divalent anion in presence of a corresponding carboxylic acid of formula (II) or (III) or (IV) to get the compound of formula (I), purifying the said compound by treating with alkali metal iodide and isolating the title compound by any conventional methods. The preparation of the said compound involves, for the first time, the intermediate formation of cis-Diiodo-trans-l-1,2-diaminocyclohexane platinum(II) and biscarboylato-trans-l-1,2-diaminocyclohexane platinum(II).